APA (7th ed.) Citation

H, K., HM, Y., EK, K., YS, R., HW, K., MS, Y., . . . BH, L. (2024). Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. Neuro-oncology, 26(12), 2352. https://doi.org/10.1093/neuonc/noae121

Chicago Style (17th ed.) Citation

H, Kim, et al. "Safety and Efficacy of Selumetinib in Pediatric and Adult Patients with Neurofibromatosis Type 1 and Plexiform Neurofibroma." Neuro-oncology 26, no. 12 (2024): 2352. https://doi.org/10.1093/neuonc/noae121.

MLA (9th ed.) Citation

H, Kim, et al. "Safety and Efficacy of Selumetinib in Pediatric and Adult Patients with Neurofibromatosis Type 1 and Plexiform Neurofibroma." Neuro-oncology, vol. 26, no. 12, 2024, p. 2352, https://doi.org/10.1093/neuonc/noae121.